Track the VERMILLION, INC. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 1 February 2016 (Acquisition). Among the most active insiders: SCHULER JACK W. The full history is free.
9
Insider Decl.
n/a
Thresholds
n/a
9 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate VERMILLION, INC. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental score
Ranked 21,985 of 28,985 companies
33.9
score / 100
Value
23
Quality
45
FCF yld-4.0%
Earn yld-5.0%
EV/EBITDA·
ROE-40%
Gross mgn64%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
57,749 sharesCommon Stock, par value $0.001 per shareSEC:0001140361-16-048188:1
Canonical exit: 18 Apr 2016 (T+90)
9 of 9 declarations
About VERMILLION, INC.
VERMILLION, INC. is a company listed on the XNAS market, specializing in the development of diagnostic solutions for women's health-related diseases. It focuses on innovation in the field of diagnostic testing.